Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED | N.MMED.WA | N.MMED.WR

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by grumpymonkey007on Dec 21, 2011 4:28pm
301 Views
Post# 19343226

RE: RE: RE: RE: RE: RE: This stock sucks

RE: RE: RE: RE: RE: RE: This stock sucksWhy did they try and imply that the increased number of stopes was going to lead to better than expected performance in Q4?Also got another one to add to the list of failures I suppose...FAILED:- 20 Dec 2011 Q4 Update. Production of 14K-15K Oz misses the revised down target of 17K-18K Oz announced 14 Nov.FAILED: - 27 Sep 2010 News Release. Brigus target steady state production for underground in Q2 2011FAILED:- 15 Nov 2010. Brigus target for 2011 production is 102-112KozLIKELY FAILURE:- 15 Nov 2010. Brigus plans for Goldfields Project to become a producing mine in 2013. The decision has been postponed until Black fox is under control.FAILED:- 31 March 2011 MD&A. Brigus communicate Q2/3/4 production target of 71-75KozFAILED:- 31 March 2011 MD&A. Q2/3/4 cost per Oz $500-550. Actual cost still >$800 at Q3FAILED:- 31 March 2011 MD&A. 2011 Production target 80-80Koz.FAILED:- 7 June 2011 Mine update. Q2 production target 16.5-18Koz. Actual production was 15.6Koz which was only 87% of 2010 Q2 productionFAILED:- 7 June 2011 Mine update. Q3 production target 26Koz.FAILED:- 7 June 2011 Mine update. 2011 production target 73- 80KozFAILED:- 7 June 2011 Mine update. Cast cost per oz $575 to $625. Actual cost still >$800 at Q3FAILED:- 14 June 2011 Q1 results. Company reiterated 2011 production 73-80KozFAIELD:- 14 June 2011 Q1 results. Company reiterated cost of $575-625 per oz.FAILED:- 14 June 2011 Q1 results. Company reiterated Q2 production at 16.5-18Koz. Actual 15.7KozFAILED:- 14 June 2011 Q1 results. Company reiterated 26Koz by Q3. Actual 16.8Koz in Q3FAILED:- 15 Aug 2011 Q2 results. Q3 production estimate 17.5Koz. Actual 16.8Koz in Q3FAILED:- 15 Aug 2011 Q2 results. Q4 production estimate 19.5Koz. Subsequently revised down 14 Nov
Bullboard Posts